| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 14710203 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 615 journal articles in the PubMed database | Email to a friend | | |
| Gori S, Colozza M, Mosconi AM, et al.
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
Br J Cancer 2004 Jan 12; 90(1):36-40.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Burris H, Yardley D, Jones S, et al.
Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
J Clin Oncol 2004 May 1; 22(9):1621-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Montemurro F, Choa G, Faggiuolo R, et al.
A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
Oncology 2004; 66(1):38-45.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Burstein HJ, Keshaviah A, Baron AD, et al.
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. [JOURNAL ARTICLE]
Cancer 2007 Jul 5.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Perez EA, Suman VJ, Rowland KM, et al.
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. [Clinical Trial, Phase II, Journal Article, Multicenter Study]
Clin Breast Cancer 2005 Dec; 6(5):425-32.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Seidman AD, Fornier MN, Esteva FJ, et al.
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
J Clin Oncol 2001 May 15; 19(10):2587-95.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Janku F, Pribylova O, Zimovjanova M, et al.
4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. [Clinical Trial, Journal Article]
Bull Cancer 2004 Oct; 91(10):E279-83.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Esteva FJ, Valero V, Booser D, et al.
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
J Clin Oncol 2002 Apr 1; 20(7):1800-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Frasci G, Comella P, D'Aiuto G, et al.
Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
Breast Cancer Res Treat 1998 May; 49(1):13-26.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
